Biomaterials for in Situ Cell Therapy

Overview

Journal BMEmat

Date 2024 Nov 22

PMID 39574564

Authors

Chang Wang

Siyu Wang

Diana D Kang

Yizhou Dong

Affiliations

Soon will be listed here.

Abstract

Cell therapy has revolutionized the treatment of various diseases, such as cancers, genetic disorders, and autoimmune diseases. Currently, most cell therapy products rely on ex vivo cell engineering, which requires sophisticated manufacturing processes and poses safety concerns. The implementation of in situ cell therapy holds the potential to overcome the current limitations of cell therapy and provides a broad range of applications and clinical feasibility in the future. A variety of biomaterials have been developed to improve the function and target delivery to specific cell types due to their excellent biocompatibility, tunable properties, and other functionalities, which provide a reliable method to achieve in vivo modulation of cell reprogramming. In this article, we summarize recent advances in biomaterials for in situ cell therapy including T cells, macrophages, dendritic cells, and stem cells reprogramming leveraging lipid nanoparticles, polymers, inorganic materials, and other biomaterials. Finally, we discuss the current challenges and future perspectives of biomaterials for in situ cell therapy.

Citing Articles

Ergothioneine attenuates psoriasis symptoms through modulation of M1/M2 macrophage polarisation via the NF-κB/JAK-STAT3 pathway.

Li A, Liu Y, Yu P, Zhang Z, Huang T, Li H Front Pharmacol. 2025; 16:1521743.

PMID: 40046751 PMC: 11880282. DOI: 10.3389/fphar.2025.1521743.

AI-driven 3D bioprinting for regenerative medicine: From bench to bedside.

Zhang Z, Zhou X, Fang Y, Xiong Z, Zhang T Bioact Mater. 2024; 45:201-230.

PMID: 39651398 PMC: 11625302. DOI: 10.1016/j.bioactmat.2024.11.021.

Natural Nano-Minerals (NNMs): Conception, Classification and Their Biomedical Composites.

Feng F, Zhang Y, Zhang X, Mu B, Qu W, Wang P ACS Omega. 2024; 9(16):17760-17783.

PMID: 38680370 PMC: 11044256. DOI: 10.1021/acsomega.4c00674.

References

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A . Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aap9630. View

Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L . Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022; 14(656):eabn1128. DOI: 10.1126/scitranslmed.abn1128. View

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

Lokugamage M, Sago C, Gan Z, Krupczak B, Dahlman J . Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands. Adv Mater. 2019; 31(41):e1902251. PMC: 6819129. DOI: 10.1002/adma.201902251. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Gao C, Cheng K, Li Y, Gong R, Zhao X, Nie G . Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy. Nano Lett. 2022; 22(22):8801-8809. DOI: 10.1021/acs.nanolett.2c01994. View

Zhang R, Qin X, Kong F, Chen P, Pan G . Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv. 2019; 26(1):328-342. PMC: 6442206. DOI: 10.1080/10717544.2019.1582730. View

Ullah I, Subbarao R, Rho G . Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015; 35(2). PMC: 4413017. DOI: 10.1042/BSR20150025. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Fang J, Hsueh Y, Soto J, Sun W, Wang J, Gu Z . Engineering Biomaterials with Micro/Nanotechnologies for Cell Reprogramming. ACS Nano. 2020; 14(2):1296-1318. PMC: 10067273. DOI: 10.1021/acsnano.9b04837. View

11.

Jain S, Tran T, Amiji M . Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials. 2015; 61:162-77. PMC: 4464978. DOI: 10.1016/j.biomaterials.2015.05.028. View

12.

Xie Y, Kim N, Nadithe V, Schalk D, Thakur A, Kilic A . Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release. 2016; 229:120-129. PMC: 4886848. DOI: 10.1016/j.jconrel.2016.03.029. View

13.

Ghorbaninezhad F, Asadzadeh Z, Masoumi J, Mokhtarzadeh A, Kazemi T, Aghebati-Maleki L . Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside. Life Sci. 2022; 297:120466. DOI: 10.1016/j.lfs.2022.120466. View

14.

Zhang L, Lin Y, Li S, Guan X, Jiang X . In Situ Reprogramming of Tumor-Associated Macrophages with Internally and Externally Engineered Exosomes. Angew Chem Int Ed Engl. 2023; 62(11):e202217089. DOI: 10.1002/anie.202217089. View

15.

Krause K, Schneider C, Kuck K, Jaquet K . Stem cell therapy in cardiovascular disorders. Cardiovasc Ther. 2010; 28(5):e101-10. DOI: 10.1111/j.1755-5922.2010.00208.x. View

16.

Gong N, Sheppard N, Billingsley M, June C, Mitchell M . Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021; 16(1):25-36. DOI: 10.1038/s41565-020-00822-y. View

17.

Lee A, Inayathullah M, Lijkwan M, Zhao X, Sun W, Park S . Prolonged survival of transplanted stem cells after ischaemic injury via the slow release of pro-survival peptides from a collagen matrix. Nat Biomed Eng. 2018; 2(2):104-113. PMC: 5927627. DOI: 10.1038/s41551-018-0191-4. View

18.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

19.

Hess K, Medintz I, Jewell C . Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today. 2020; 27:73-98. PMC: 7156029. DOI: 10.1016/j.nantod.2019.04.005. View

20.

Zhao Z, Ukidve A, Kim J, Mitragotri S . Targeting Strategies for Tissue-Specific Drug Delivery. Cell. 2020; 181(1):151-167. DOI: 10.1016/j.cell.2020.02.001. View